A5026206202- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- HIV/AIDS drug development and treatment
- Polyomavirus and related diseases
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Transplantation: Methods and Outcomes
- Hematological disorders and diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Clostridium difficile and Clostridium perfringens research
- Peptidase Inhibition and Analysis
- Mast cells and histamine
- Ubiquitin and proteasome pathways
- Viral-associated cancers and disorders
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cell death mechanisms and regulation
- COVID-19 Clinical Research Studies
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Venous Thromboembolism Diagnosis and Management
Loyola University Medical Center
2017-2024
Loyola University Chicago
2016-2024
Loyola Medicine
2024
Dana-Farber Cancer Institute
2022
Minnesota Oncology
2015
University of Minnesota
2014
Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy maribavir with fewer treatment-limiting toxicities than valganciclovir.
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of pre-leukemic hematopoietic disorders characterized by cytopenia in peripheral blood due to ineffective hematopoiesis and normo- or hypercellularity morphologic dysplasia bone marrow (BM). An inflammatory BM microenvironment programmed cell death stem/progenitor cells (HSPCs) thought be the major causes MDS. Pyroptosis, apoptosis necroptosis (collectively, PANoptosis) observed tissues MDS patients, suggesting an important...
Myeloid sarcoma (MS) is a rare disease entity identified as variety of manifestations defined by the occurrence extramedullary myeloid cell masses with or without bone marrow involvement. This case describes an unusual presentation isolated MS in 60-year-old otherwise healthy male, who initially presented to his primary care physician vague abdominal pain. After extensive workup including three omental biopsies, umbilical core biopsy, and inguinal lymph node he was ultimately diagnosed tumor...
This study aimed to assess the risk of maintenance immunosuppression on post-transplant malignancy across all solid organ transplant types.This is a retrospective cohort from multicenter hospital system in United States. The electronic health record was queried 2000 2021 for cases transplant, immunosuppressive medications, and malignancy.A total 5,591 patients, 6,142 transplanted organs, 517 malignancies were identified. Skin cancer most common type at 52.8%, whereas liver first present...
Lymphoid-primed multipotent progenitor (LMPP)-like and granulocyte-monocyte (GMP)-like leukemia stem cells (LSCs) co-exist in the blood of most patients with acute myeloid (AML). Complete elimination both types LSCs is required to cure AML. Using an MLL-AF9-induced murine AML model, we studied role hematopoietic cytokines survival LMPP- GMP-like LSCs. We found that SCF or FLT3L promotes LMPP-like by stimulating Stat5-mediated Mcl1 expression, whereas interleukin-3 (IL-3) IL-6 induces...
Melphalan at a dose of 200 mg/m2 (MEL200) remains the standard high therapy before autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Intensifying regimen has shown promising results. We report here 7-year follow up our novel busulfan and melphalan followed by bortezomib (BuMelVel). Forty-three MM patients received BuMelVel with pharmacokinetic adjusted busulfan. Outcomes were compared to matched control cohort from CIBMTR database (n = 162) receiving MEL200. The primary...
Summary The standard of care for fit, newly diagnosed multiple myeloma patients includes induction therapy followed by consolidative high‐dose chemotherapy with melphalan and autologous stem cell transplant (AHSCT). Intensified preparative regimens, such as busulfan (BuMel), have shown promise to lengthen progression‐free survival (PFS). We previously reported that the addition bortezomib BuMel improved PFS compared alone in CIBMTR‐matched controls. now integrate second‐generation protease...
Multiple myeloma is a neoplastic disorder of plasma cells typically afflicting older individuals. Despite significant improvements in induction therapy and outcomes for transplant-ineligible newly diagnosed multiple (NDMM) patients, autologous stem cell transplant (ASCT) remains the standard care consolidation transplant-eligible NDMM. Consequently, optimal approach to mobilization critical. In this manuscript, we outline key updates NDMM patients. We describe number cycles prior...